WO2006103702A2 - Enhanced bio-adherent polymeric compositions for coating mucosal and epidermal epithelium - Google Patents
Enhanced bio-adherent polymeric compositions for coating mucosal and epidermal epithelium Download PDFInfo
- Publication number
- WO2006103702A2 WO2006103702A2 PCT/IN2006/000112 IN2006000112W WO2006103702A2 WO 2006103702 A2 WO2006103702 A2 WO 2006103702A2 IN 2006000112 W IN2006000112 W IN 2006000112W WO 2006103702 A2 WO2006103702 A2 WO 2006103702A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sucralfate
- weight
- sucrose octasulfate
- composition according
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
Definitions
- the present invention relates to enhanced bio-adherent polymeric pharmaceutical compositions particularly useful to provide protective or curative coating to the epithelial surfaces, especially in humans. More particularly the present invention relates to pharmaceutical compositions with enhanced bio-adherence.
- the present invention further relates to a process for the manufacture of enhanced bio-adherent polymeric compositions particularly useful to provide protective or curative coating to the epithelial surfaces, especially in humans.
- the epithelial surfaces are of two types. Firstly there is the mucosal type which includes those of the naso-pharynx, oro-pharynx, gastrointestinal tract, cysto-urinary and vaginal linings. Secondly, there is the epidermal type of epithelium which includes those external areas of skin directly exposed to ambient environment.
- U.S. 5,447,918, specifically Example 1 and Example 12 teaches agents including sucrose octasulfate as the functionalized carbohydrates and is found in practice to have enhanced tissue adherence and coating when combined, with citrate. This observation was not limited to citrate but observed also with fumarate, succinate, malate, alpha-keto-gluturate, that is all Kreb's cycle acids (KCA). In addition to this, combinations involving sucrose octasulfate or sucralfate formulated in accordance to Example 7 U.S. 5,447,918) is noted to have unimpeded absorption of cimetidine, ranitidine, nizatidine and omeprazole from the gastrointestinal (Gl) tract.
- Gl gastrointestinal
- Yet another object of the present invention is to provide a novel pharmaceutical composition of sucralfate which can be administered simultaneously with other medications without the known non-specific adsorption of these medications on sucralfate i.e entrapment.
- an enhanced bioadherent polymeric pharmaceutical compositions adapted to provide selectively protective and /or curative epithelial coatings , comprising : i) anionic species of saccharides or sugars duly anionic by virtue of covalently bonded polarizable substituents selected from sucralfate, sucrose octasulfate and its salts, ii) emulsified blend of a hygroscopic agent, amylodextrin starch and poly- hydroxyl compound in a weight to weight to weight ratio range from 1:1 :10 to 1:4:8. ; iii) one or more anti irritants selected from a) antacid compounds, b) acid reducers; c) proton pump inhibitors; d) phytotherapeutic herbals and e) anti-neoplastic agents.
- a composition comprising sucralfate or sucrose octasulfate in combination with one or more anti-irritant agents in a weight to weight ratio of between 3:1 to 1:6 of sucralfate or sucrose octasulfate to anti-irritant agent, said composition being in either liquid or solid dose form, wherein the anti-irritant agent is one or more taken from the group comprising of a) antacid compounds: b) acid reducers: c) proton pump inhibitors; d) and phytotherapeutic herbals:
- a process for preparation of enhanced bioadherent polymeric pharmaceutical compositions adapted to provide selectively protective and /or curative epithelial coatings said process comprising mixing i) anionic species of saccharides or sugars duly anionic by virtue of covalently bonded polarizable substituents selected from sucralfate, sucrose octasulfate and its salts, ii
- composition comprising sucralfate or sucrose octasulfate, anti-irritants selected from 1) antacids, such as citrate, malate, magnesium hydroxide, calcium carbonate, malgadrate, glycine, magnesium carbonate, and other Kreb's cycle acids;
- antacids such as citrate, malate, magnesium hydroxide, calcium carbonate, malgadrate, glycine, magnesium carbonate, and other Kreb's cycle acids
- phytotherapeutic herbals like licorice, chamomile, saw palmetto, oryzonol, alginate, slippery elm bark and
- composition of this invention is in either liquid or solid dose form specifically formulated such that the weight/weight ratio for functionalized carbohydrates like sucralfate and sucrose octasulfate and the anti irritant agents listed would range respectively from 10:1 to 1:10, preferably 5:1 to 1:6, most preferably 3:1 to 1:6 in either liquid or solid dose form.
- the anti-irritant relieving agents are selected from one or more of the following group that include 1) antacids, such as citrate, malate, magnesium hydroxide, calcium carbonate, malgadrate, glycine, magnesium carbonate, Kreb's cycle acids 2) acid reducers like cimetidine, ranitidine, nizatidine, and famotidine 3) proton pump inhibitors omeprazole, esomeprazole, pantoprazole, rabeprazole, and lansoprazole 4) phytotherapeutic herbals like licorice, chamomile, saw palmetto, oryzonol, alginate, slippery elm bark and 5)anti-neoplastic agents like Vincristine, Vinblastine, 6-thioguanine, Tamoxifen, Procarbazine, Prednisone, Paclitaxel, Mercaptopurine, Mitoxantrone, Floxuridine, Altretamine, Carboplatin, Doxor
- the sugars are selected from monosaccharide, polysaccharides, proteo- saccharides, but preferably dissacharides, specifically sucrose; the covalently bonded polarizable substituents being oxylated or aminated variety, particularly carbamic, carboxylic, sulfonic, or phosphoric type and specifically sulfate variety of polarizable substituent.
- a preferred anionic species embodying this component of the invention is sucrose octasulfate or any of its salts such as sucralfate which is the aluminum hydroxide salt of sucrose octasulfate.
- Emulsifying agents that work well for this component of the invention are xanthum gum, poly ethylene glycol (PEG), carboxy-methylcellulose, carboxy- cellulose, arreagan, mucilaginous, pectinaceous glycosylated proteins or proteoglycans.
- Starches that accommodate the purpose of this component of the invention include amylodextrins sourced from corn, maize, wheat, rice or potato.
- Poly hydroxyl compound that work well for this component of the invention is monosacharride, dissacharides or polysaccarides.
- the emulsifying/hygroscopic agents are adapted to provide an emulsion effect of diminished chalkiness when using magnesium hydroxide.
- the composition further comprises antimicrobial agents suitable for eliminating microbial-mediated processes in inflamed gastrointestinal tracts or on mucosal or epithelial surfaces.
- antimicrobial agents suitable for eliminating microbial-mediated processes in inflamed gastrointestinal tracts or on mucosal or epithelial surfaces.
- the anti-irritant role of antacid group is three-fold.
- One purpose is to produce immediate neutralization of acid.
- a second purpose is to elevate the potency of functionalized poly/disaccharides, namely sucralfate and sucrose octasulfate, by promoting hydrogen-bonded and metal chelated polymerization of sucralfate or sucrose octasulfate in solution, which in turn when administered either orally or topically on ulcerated epithelial surfaces, higher concentrations of the functionalized poly/disaccharide would be achieved.
- the third purpose is to mutually distract the antacid compounds and sucralfate or sucrose octasulfate compounds from electrostatic adsorption of concomitantly administered drugs.
- both the antacid and sucralfate or sucrose octatasulfate are present between weight to weight ratios of 1:2 to 1:5 [antacid to sucralfate or sucrose octasulfate], the concomitantly administered acid reducers and proton pump inhibitors do not adsorb to either the antacid or to sucralfate or sucrose octatsulfate, thus remaining free in solution for uptake into the bloodstream from the Gl tract.
- the role of the acid reducers and proton pump inhibitors is to provide prolonged reduction in the hydrocholoric acid irritant in the Gl tract.
- the role of the phytotherapeutic herbals is to improve the mucus gel barrier in the Gl tract and to diminish inflammation on ulcerated epithelium.
- compositions of the present invention improves potency of sucralfate, permits concomitant administration of antacids compounds and proton pump inhibitors or histamine-2 blockers, and relieves nausea, vomiting and diarrhea in patients who suffer from erosive as well as non-erosive gastroesophageal reflux syndrome (GERD).
- GEF gastroesophageal reflux syndrome
- compositions of enhanced bio-adherence of present invention may be dry loose granulated, powdered, tabletted or encapsulated.
- Compositions may be liquid in aqueous single phase, aqueous suspension or aqueous emulsion.
- Compositions may be in ointment or cream form with petroleum or non-petroleum base.
- the compositions have enhanced bio-adherence such that when applied such compositions will coat the epithelium to effect protection or cure from noxious, erosive, inflammatory or infectious injury.
- compositions may be effected by oral consumptions.
- Compositions may be applied topically in the case of epidermal epithelium or by extrusion/introduction through an orifice in the case of indwelling mucosal surfaces of urinary bladder or vaginal vault or colon.
- the process of present invention comprise mixing the components as mentioned above in the given proportion. It is then tabletted, encapsulated or converted to the liquid form or to the form of ointment by conventional methods.
- Sucralfate is of a class of cyto-therapeutic agents whose pharmacologic is solely on the basis of bio-adherence. Common drug of effects of sucralfate is due in part to its surface bio-adherence.
- compositions which contain sucralfate or sucrose octasulfate. It should be borne in mind, however, that other carbohydrate poly sulfonates could be used as well. Additionally that the use of other KCA's such as citrate, fumarate, succinate, oxalate, malate or alpha keto glutarate could be substituted with compounds that replace the carboxylate groups with carbamide, phosphonic, phosphate or even sulfonic, sulfonate substituents.
- Example 1 Liquid Formulation
- xanthum gum and starch and sucrose octasulfate are in weight ratios vary from 1:1:10 to 1:4:8 and provide for an emulsion that is particularly smooth to taste, less gritty and chalky when using magnesium hydroxide.
- the increase concentration of starch in the presence of xanthum gum and sucrose octasulfate appear key.
- Example 3 Acid Reducer Formulation
- a 1 cm square section of Gl tract was examined for the content of adherent aluminum both in the ulcer crater and in surrounding normal tissue. Concentration of adherent aluminum was assayed by atomic absorption spectroscopy then correlated to sucralfate concentration.
- Example No. 6 Formulation of US Patent 5,447,918 containing malate, (Example No. 2 above), manufactured by Sterling Foster Pharmaceutical and Glen Copel Pharmaceutical USA marketed under trade name Gastrafate Rx appear to concentrate on normal un-injured Gl tract 6-7x's and 3-4x's greater than generic sucralfate suspension and sucralfate antacid suspension. Gastrafate concentrate on acid-injured Gl tract 23x's greater and 8-9x's greater than generic sucralfate suspension and sucralfate antacid suspension. Similar results were seen using sucrose octasulfate instead of sucralfate. UNIMPEDED UPTAKE OF ACID REDUCERS
- sucralfate or magnesium hydroxide/ aluminum hydroxide antacid When given alone with either sucralfate or magnesium hydroxide/ aluminum hydroxide antacid, fifteen to twenty percent, 15-20%, of dissolved cimetidine, ranitidine, and famotidine was not absorbed from the Gl tract into the blood stream. However when sucralfate or sucrose octasulfate was coadministered with magnesium hydroxide/aluminum hydroxide, this diminution of uptake of cimetidine and ranitidine disappeared. It appears sucralfate and antacid at a weightweight ratio of 4:1 to 2:1 mutually distract each other thus allowing dissolved histamine-2 blockers to be freely absorbed from the Gl tract.
- Example No. 6 Formulation of US Patent 5,447,918 containing malate (Example No. 2 above) was tested against placebo in the treatment of symptoms of GERD. Symptom relief included relief of chest pain, heartburn sensation, and acid regurgitation.
- compositions of enhanced bio-adherence are useful in the treatment of oral, nasal, vaginal, cysto-mucosal, dermatological irritation, infection, erosions, ulcerations or lacerations.
- the clinical effects of enhanced bio-adherence is immediate symptomatic relief, accelerated healing, relief of conditions resulting 0 from noxious injury to the epithelium.
- composition of the present invention was compared with those containing sucralfate and with that of the US'918.
- the effects of the composition were evaluated in terms of bioadherence, time taken for healing of erosions, pain improvements, relief of nausea and vomiting, bowel habits and reduction of 5 Helibacter pylori.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN262/KOL/2005 | 2005-04-01 | ||
IN262KO2005 | 2005-04-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006103702A2 true WO2006103702A2 (en) | 2006-10-05 |
WO2006103702A3 WO2006103702A3 (en) | 2006-12-21 |
Family
ID=36794936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2006/000112 WO2006103702A2 (en) | 2005-04-01 | 2006-03-31 | Enhanced bio-adherent polymeric compositions for coating mucosal and epidermal epithelium |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2006103702A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2214677A2 (en) * | 2007-11-13 | 2010-08-11 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
WO2011083291A1 (en) * | 2010-01-07 | 2011-07-14 | Julian Manuel Galvez | Combinations comprising an ant i -inflammatory agent and/or an antibacterial agent and a glycosylamine and their use in medicine |
US8617618B2 (en) * | 2007-03-29 | 2013-12-31 | Difass International S.R.L. | Topical compositions containing magaldrate |
US9050368B2 (en) | 2007-11-13 | 2015-06-09 | Meritage Pharma, Inc. | Corticosteroid compositions |
JP2016525127A (en) * | 2013-07-19 | 2016-08-22 | マッカロー、リッキーMCCULLOUGH,Ricky | Immunomodulators for the treatment of functional epithelial syndrome |
US11413296B2 (en) | 2005-11-12 | 2022-08-16 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0431877A1 (en) * | 1989-12-05 | 1991-06-12 | Smithkline Beecham Laboratoires Pharmaceutiques | Cimetidine pharmaceutical compositions |
US5447918A (en) * | 1992-07-27 | 1995-09-05 | Mccullough; Ricky W. | Gastrointestinal anti-irritant composition comprising sucralfate and methods of use |
US5464828A (en) * | 1988-03-02 | 1995-11-07 | Chugai Pharmaceutical Co., Ltd. | Aqueous suspension of sucralfate |
US5593696A (en) * | 1994-11-21 | 1997-01-14 | Mcneil-Ppc, Inc. | Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders |
EP0974361A1 (en) * | 1996-02-08 | 2000-01-26 | Chugai Seiyaku Kabushiki Kaisha | Method of using antacid agent and pharmaceutical preparation containing antacid agent |
EP1000614A1 (en) * | 1997-06-30 | 2000-05-17 | Chugai Seiyaku Kabushiki Kaisha | Sucralfate-containing composition and process for the preparation thereof |
WO2000078307A1 (en) * | 1999-06-21 | 2000-12-28 | Daewoong Pharmaceutical Co., Ltd. | Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate |
-
2006
- 2006-03-31 WO PCT/IN2006/000112 patent/WO2006103702A2/en active Search and Examination
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5464828A (en) * | 1988-03-02 | 1995-11-07 | Chugai Pharmaceutical Co., Ltd. | Aqueous suspension of sucralfate |
EP0431877A1 (en) * | 1989-12-05 | 1991-06-12 | Smithkline Beecham Laboratoires Pharmaceutiques | Cimetidine pharmaceutical compositions |
US5447918A (en) * | 1992-07-27 | 1995-09-05 | Mccullough; Ricky W. | Gastrointestinal anti-irritant composition comprising sucralfate and methods of use |
US5593696A (en) * | 1994-11-21 | 1997-01-14 | Mcneil-Ppc, Inc. | Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders |
EP0974361A1 (en) * | 1996-02-08 | 2000-01-26 | Chugai Seiyaku Kabushiki Kaisha | Method of using antacid agent and pharmaceutical preparation containing antacid agent |
EP1000614A1 (en) * | 1997-06-30 | 2000-05-17 | Chugai Seiyaku Kabushiki Kaisha | Sucralfate-containing composition and process for the preparation thereof |
WO2000078307A1 (en) * | 1999-06-21 | 2000-12-28 | Daewoong Pharmaceutical Co., Ltd. | Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11413296B2 (en) | 2005-11-12 | 2022-08-16 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US8617618B2 (en) * | 2007-03-29 | 2013-12-31 | Difass International S.R.L. | Topical compositions containing magaldrate |
EP2214677A2 (en) * | 2007-11-13 | 2010-08-11 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
EP2214677A4 (en) * | 2007-11-13 | 2013-09-25 | Meritage Pharma Inc | Compositions for the treatment of inflammation of the gastrointestinal tract |
US9050368B2 (en) | 2007-11-13 | 2015-06-09 | Meritage Pharma, Inc. | Corticosteroid compositions |
US10293052B2 (en) | 2007-11-13 | 2019-05-21 | Meritage Pharma, Inc. | Compositions for the treatment of gastrointestinal inflammation |
US11357859B2 (en) | 2007-11-13 | 2022-06-14 | Viropharma Biologics Llc | Compositions for the treatment of gastrointestinal inflammation |
WO2011083291A1 (en) * | 2010-01-07 | 2011-07-14 | Julian Manuel Galvez | Combinations comprising an ant i -inflammatory agent and/or an antibacterial agent and a glycosylamine and their use in medicine |
JP2016525127A (en) * | 2013-07-19 | 2016-08-22 | マッカロー、リッキーMCCULLOUGH,Ricky | Immunomodulators for the treatment of functional epithelial syndrome |
EP3021671A4 (en) * | 2013-07-19 | 2017-03-01 | McCullough, Ricky W. | Immuno-modulators for treating functional epithelial syndromes |
Also Published As
Publication number | Publication date |
---|---|
WO2006103702A3 (en) | 2006-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006103702A2 (en) | Enhanced bio-adherent polymeric compositions for coating mucosal and epidermal epithelium | |
WO2019155389A1 (en) | An aqueous mucoadhesive and bioadhesive composition for the treatment | |
EP3429607B1 (en) | Compositions useful in the prevention and/or treatment of disorders of the oral cavity, upper airways and esophagus | |
JP2002523354A (en) | Liquid mucoadhesive composition for oral cavity | |
AU2014385792B2 (en) | Composition and method for enhancing wound healing | |
EP2429517B1 (en) | Compositions suitable for the topical treatment of fungal infections of the skin and nails | |
EP2139451B1 (en) | Topical compositions containing magaldrate | |
KR101861347B1 (en) | Compositions for the treatment of peripheral ulcers of various origins | |
US7795239B2 (en) | Saccharide compositions and method of use | |
MX2011001812A (en) | Topical hydrogel composition. | |
EP3370700B1 (en) | Oral gel composition comprising chitosan, pectin, l-carnitine and n-acetylcysteine | |
CN1302813C (en) | Transmission system for medicine containing trehalose and hyaluronic acid in use for curing burn and preparing method | |
EP2737902A1 (en) | Compositions comprising cimetidine and n,o-carboxymethyl chitosan for the prevention and therapy of pathologies of the skin and the mucous membranes and in the odontostomatological field | |
CN108136210B (en) | Tannin-containing composition | |
FR2793685A1 (en) | Buffered solid and liquid compositions containing phloroglucinol, for oral treatment of spasmodic disorders | |
RU2536266C2 (en) | Cream for medicinal purposes, made with application of framycetin sulfate and chitosan | |
JP5930332B2 (en) | Use of sprayable compositions comprising ambroxol | |
EP3103438B1 (en) | Topical nasal compositions containing xyloglucans for use as decongestans | |
CN1470246A (en) | Liquid antiacid composition | |
EP3129031A1 (en) | Composition for treating stomach pain | |
ITMI20111168A1 (en) | PHARMACEUTICAL COMPOSITIONS INCLUDING HYDROXYPROPYLMETHYLCELLULA AND / OR HYALURONIC ACID AND THEIR USE | |
CN115209954A (en) | Composition for treating respiratory disorders | |
WO2014171201A1 (en) | Oral phosphorus-adsorbing agent of low calcium absorption type | |
UA115118U (en) | MEDICINAL PRODUCT IN THE FORM OF CONCENTRATE FOR PREPARATION OF THE INFUSION SOLUTION | |
AU2004222773A1 (en) | A method for treatment of mouth lesions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
NENP | Non-entry into the national phase in: |
Ref country code: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4166/KOLNP/2007 Country of ref document: IN |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: RU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06728417 Country of ref document: EP Kind code of ref document: A2 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 6728417 Country of ref document: EP |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) |